A Multi Modality Surveillance Program for Women At High Risk for Breast Cancer



Status:Active, not recruiting
Conditions:Breast Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:5/4/2018
Start Date:June 2004
End Date:February 2027

Use our guide to learn which trials are right for you!

The purpose of this study is to develop a coordinated, standardized screening program for the
early detection of breast cancer in high-risk women. This would include Breast Mammography
and Magnetic Resonance Imaging (MRI) examination of your breasts. The University of Chicago
Department of Radiology is performing research to develop better ways of imaging the breast.
The investigators would like to be able to reliably identify abnormal tissue and determine
whether abnormal areas contain cancer without surgical procedures (i.e., a biopsy which
involves removing breast tissue with a needle or surgical instrument). Annual mammography has
already been recommended for the patient based on family history or personal history of
cancer. In young women, dense breasts sometimes make it difficult to find abnormal changes on
breast cancer screening (mammograms). MRI, in combination with mammography, may increase the
rate of detection of early cancers. In addition, MRI can provide better images of breast
tissue. The investigators hope to prove that combining multiple screening measures including
biomarkers improves the chances that, if you have a small cancer or pre-cancer, it will be
found early. This study will also evaluate quality of life measures during breast cancer
screening and compare breast MRI and mammogram in a high-risk population. The investigators
will establish a database of clinical characteristics, blood biomarkers and interventions
that will be saved for future analysis and aid in the development of more effective screening
in high-risk women. This research will also help us develop tools for studies in the future.


Inclusion Criteria:

Each woman will meet one or more of the criteria below:

- Known BRCA1 or BRCA2 carrier (must be older than 21 years)

- Any mutation carrier in hereditary breast cancer susceptibility genes that is known to
increase the risk for breast cancer (regardless of age). Some examples of these would
include TP53, PTEN, BRCA1 and BRCA2, CHEK2, ATM, and CDH1 and other identified genetic
markers conferring greater than 2.5 fold increased breast cancer risk in a polygenic
model.

- For women who chose not to have genetic testing or test negative, probability of being
a BRCA1 or BRCA2 carrier of 20% or greater based on BRCAPRO analysis or ≥ 25% risk of
being a mutation carrier by any Genetic model such as Couch, Myriad, BODICEA, in
addition to a lifetime breast cancer risk >=20% by CARE, Tyler Cuzick, or Claus model

- Personal history of breast cancer before age 35 years and no evidence of disease
recurrence for at least two years.

- Any woman of African ancestry whose 1st degree relative (mother or sister) or 2nd
degree relative (aunt, grandmother) if paternal lineage suspected diagnosed with
breast cancer under age 40, regardless of risk model calculation

- Have a personal history of ductal carcinoma in situ (DCIS) diagnosed at or before age
35 AND a first degree relative who had been diagnosed with breast cancer before age 50
OR has a first degree relative diagnosed with ovarian cancer at any age

- Any female cancer survivor who received chest irradiation before age 30 for any
disease including Hodgkin's, a sarcoma, neuroblastoma, or other medical condition.

In addition to meeting one of the above criteria, women must meet all of the following:

- willing to travel to University of Chicago Medical Center for imaging studies as well
as any necessary follow-up procedures.

- have at least one breast that has not been irradiated for cancer

- be at least 25 years of age or at least 5 years younger than the first case of breast
cancer diagnosis in the family. (This applies only to high risk women who are not
BRCA1 or BRCA2 mutation carriers)

- be able to give informed consent

Exclusion Criteria:

Women will be excluded if they meet one of the following:

- active cancer at the time of enrollment. A prior history of breast cancer is permitted
if the subject has completed chemotherapy and is considered disease-free at the time
of enrollment.

- current pregnancy or plans for pregnancy within two years of enrollment

- presence of a pacemaker or any other metallic foreign objects in their body that
interferes with an MRI

- breast surgery within two weeks of study entry

- previous bilateral mastectomy (prophylactic or therapeutic)

- history of kidney disease or abnormal kidney tests

- Women who test negative in a family with identifiable BRCA mutations are ineligible
regardless of risk calculation
We found this trial at
1
site
5801 South Ellis Avenue
Chicago, Illinois 60637
 773.702.1234
Phone: 773-702-0681
University of Chicago One of the world's premier academic and research institutions, the University of...
?
mi
from
Chicago, IL
Click here to add this to my saved trials